Medicaid Drug Rebate Program - Manufacturers and Supporting Regulation at 42 CFR 447.534 (CMS-367)

ICR 201308-0938-021

OMB: 0938-0578

Federal Form Document

Forms and Documents
Document
Name
Status
Supporting Statement A
2013-08-15
ICR Details
0938-0578 201308-0938-021
Historical Active 201203-0938-005
HHS/CMS 20301
Medicaid Drug Rebate Program - Manufacturers and Supporting Regulation at 42 CFR 447.534 (CMS-367)
Extension without change of a currently approved collection   No
Regular
Approved without change 09/20/2013
Retrieve Notice of Action (NOA) 08/20/2013
  Inventory as of this Action Requested Previously Approved
09/30/2016 36 Months From Approved 11/30/2013
9,440 0 9,280
139,712 0 137,344
0 0 8,240,640

Section 1927 requires drug manufactures to enter into and have in effect a rebate agreement with the Federal Government for States to receive funding for drugs dispensed to Medicaid recipients. In order for payment to be made under Medicaid, the drug labeler must complete and sign a drug rebate agreement and fillin the information on the related documents. The Affordable Care Act (ACA) added two new data elements to potentially be reported by manufacturers, a Pediatric Exclusivity product indicator and a new optional "ACA base AMP" field. Additionally, per the ACA, the Federal upper limit (FUL) will be calculated as no less than 175 percent of the weighted average of the most recently reported monthly AMP. Section 1927 of the Act requires manufacturers to report the total number of units that are used to calculate monthly AMP for each covered outpatient drug no later than 30 days after the last day of the month. We plan to require manufacturers to report these units by the same unit type used to calculate the AMP and to use these units to calculate the weighted-AMP-based FULs prices.

Statute at Large: 19 Stat. 1927 Name of Statute: null
  
None

Not associated with rulemaking

  78 FR 32659 05/31/2013
78 FR 48686 08/09/2013
No

1
IC Title Form No. Form Name
Medicaid Drug Rebate Program - Manufacturers and Supporting Regulation at 42 CFR 447.534 CMS-367a, -367b, -367c, and -367d Medicaid Drug Program Monthly and Quarterly Drug Reporting Format

  Total Approved Previously Approved Change Due to New Statute Change Due to Agency Discretion Change Due to Adjustment in Estimate Change Due to Potential Violation of the PRA
Annual Number of Responses 9,440 9,280 0 0 160 0
Annual Time Burden (Hours) 139,712 137,344 0 0 2,368 0
Annual Cost Burden (Dollars) 0 8,240,640 0 0 -8,240,640 0
No
No
There are no new systems collections or program changes. The number of labelers has increased from 580 to 590 labelers, thereby causing a corresponding rise in our burden estimates. The cost burden has been adjusted downward to zero as it was erroneously included in previous submissions. There are no costs, other than labor costs, associated with this information collection request at this time.

$0
No
No
No
No
No
Uncollected
Mitch Bryman 410 786-5258 [email protected]

  No

On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
 
 
 
 
 
 
 
    (i) Why the information is being collected;
    (ii) Use of information;
    (iii) Burden estimate;
    (iv) Nature of response (voluntary, required for a benefit, or mandatory);
    (v) Nature and extent of confidentiality; and
    (vi) Need to display currently valid OMB control number;
 
 
 
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.
08/20/2013


© 2024 OMB.report | Privacy Policy